Compile Data Set for Download or QSAR
maximum 50k data
Found 33 Enz. Inhib. hit(s) with all data for entry = 1536
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330225(US10301336, Comp No. 1 | US9663543, Compound 1 | d...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330257(US10301336, Comp No. 33 | US9663543, Compound 33 |...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330227(3-acetyl-1-(2-((2S,4R)-2-(3- chloro-2- fluorobenzy...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330228(((3-acetyl-1-(2-((2S,4R)-2- (3-chloro-2- fluoroben...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330226(US10301336, Comp No. 2 | US9663543, Compound 2 | e...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330256(1-(2-((2S,4R)-2-(3-chloro- 2-fluorobenzylcarbamoyl...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330255(3-acetyl-1-(2-((2S,4R)-2-(3- chloro-2- fluorobenzy...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330254(US10301336, Comp No. 30 | US9663543, Compound 30 |...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330230(((3-acetyl-1-(2-((2S,4R)-2- (3-chloro-2- fluoroben...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330231(3-acetyl-1-(2- ((2S,3aR,6aR)-2-(3-chloro- 2- fluor...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330232(US10301336, Comp No. 8 | US9663543, Compound 8 | d...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330234(3-acetyl-1-(2-((2S,4R)-2-(3- chloro-2- fluorobenzy...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330237(US10301336, Comp No. 13 | US9663543, Compound 13 |...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330238(1-(2-((2S,4R)-2-(3-chloro- 2-fluorobenzylcarbamoyl...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330239(US10301336, Comp No. 15 | US9663543, Compound 15 |...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330240(3-carbamoyl-1-(2-((2S,4R)- 2-(3-chloro-2- fluorobe...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330241(US10301336, Comp No. 17 | US9663543, Compound 17 |...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330242(3-carbamoyl-1-(2-((2S,4R)- 2-(3-chloro-2- fluorobe...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330243(US10301336, Comp No. 19 | US9663543, Compound 19 |...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330244(US10301336, Comp No. 20 | US9663543, Compound 20 |...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330245(US10301336, Comp No. 21 | US9663543, Compound 21 |...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330246(((3-acetyl-1-(2-((2S,4R)-2- (3-chloro-2- fluoroben...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330247(US10301336, Comp No. 23 | US9663543, Compound 23 |...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330248(US10301336, Comp No. 24 | US9663543, Compound 24 |...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330249(3-acetyl-1-(2-((2S,4R)-2-(3- chloro-2- fluorobenzy...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330250(((3-acetyl-1-(2-((2S,4R)-2- (3-chloro-2- fluoroben...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330251(3-acetyl-1-(2-((2S,4R)-2-(3- chloro-2- fluorobenzy...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330252(((3-acetyl-1-(2-((2S,4R)-2- (3-chloro-2- fluoroben...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330253(2,2,2-trifluoroethyl hydrogen 3-acetyl-1-(2- ((2S,...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330229(US10301336, Comp No. 5 | US9663543, Compound 5 | d...)
Affinity DataIC50:  5.50E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330235(US10301336, Comp No. 11 | US9663543, Compound 11 |...)
Affinity DataIC50: >1.00E+4nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330236(1-(2-((2S,4R)-2-(3-chloro- 2-fluorobenzylcarbamoyl...)
Affinity DataIC50: >1.00E+4nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM330233(US10301336, Comp No. 9 | US9663543, Compound 9 | e...)
Affinity DataIC50: >1.00E+4nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent